Gottfried Rudofsky, Markus Menzen, Louis Potier, Andrei-Mircea Catarig, Alice Clark, Prachi Priyadarshini, Cristina Abreu
{"title":"胰高血糖素样肽-1受体激动剂-经验丰富的成人2型糖尿病患者在现实世界环境中转换为每周一次的西马鲁肽：SURE项目事后分析","authors":"Gottfried Rudofsky, Markus Menzen, Louis Potier, Andrei-Mircea Catarig, Alice Clark, Prachi Priyadarshini, Cristina Abreu","doi":"10.1007/s12325-024-03000-x","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>To investigate outcomes in adults with type 2 diabetes who switched to once-weekly (OW) semaglutide from another glucagon-like peptide-1 receptor agonist (GLP-1RA) in clinical practice.</p><h3>Methods</h3><p>This post hoc analysis used data from the SemaglUtide Real-world Evidence (SURE) program, which included nine observational studies investigating the initiation of OW semaglutide in people with type 2 diabetes in routine clinical practice. Using a random coefficient-adjusted mixed model for repeated measurements, changes in glycosylated hemoglobin (HbA<sub>1c</sub>), body weight, and body mass index were analyzed for GLP-1RA-experienced patients who had at least one documented HbA<sub>1c</sub> value within the 12 weeks before switching to OW semaglutide. In addition, descriptive statistics were used for HbA<sub>1c</sub>, body weight target achievement, and safety data.</p><h3>Results</h3><p>Of the 3,505 patients included in the nine SURE studies, 651 switched to OW semaglutide from another GLP-1RA. GLP-1RA-experienced patients who switched to OW semaglutide demonstrated a 0.67%-point [95% confidence interval (CI) − 0.74; − 0.60, <i>p</i> < 0.0001] reduction in HbA<sub>1c</sub>, and a 3.69-kg [95% CI − 3.98; − 3.41, <i>p</i> < 0.0001] reduction in body weight over 30 weeks. A body weight reduction of ≥ 5% was achieved by 27.6% of patients, and 33.3% of patients with baseline HbA<sub>1c</sub> ≥ 7% achieved HbA<sub>1c</sub> < 7% at end of study. No new safety concerns were identified.</p><h3>Conclusions</h3><p>Data from this post hoc analysis suggest that, for those not adequately responding to treatment with other GLP-1RAs, switching to OW semaglutide could provide additional glycemic and weight benefits with the convenience of an OW dosing regimen.</p><h3>Graphical abstract</h3><p>A graphical abstract is available with this article.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 2","pages":"788 - 800"},"PeriodicalIF":3.4000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-024-03000-x.pdf","citationCount":"0","resultStr":"{\"title\":\"Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis\",\"authors\":\"Gottfried Rudofsky, Markus Menzen, Louis Potier, Andrei-Mircea Catarig, Alice Clark, Prachi Priyadarshini, Cristina Abreu\",\"doi\":\"10.1007/s12325-024-03000-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>To investigate outcomes in adults with type 2 diabetes who switched to once-weekly (OW) semaglutide from another glucagon-like peptide-1 receptor agonist (GLP-1RA) in clinical practice.</p><h3>Methods</h3><p>This post hoc analysis used data from the SemaglUtide Real-world Evidence (SURE) program, which included nine observational studies investigating the initiation of OW semaglutide in people with type 2 diabetes in routine clinical practice. Using a random coefficient-adjusted mixed model for repeated measurements, changes in glycosylated hemoglobin (HbA<sub>1c</sub>), body weight, and body mass index were analyzed for GLP-1RA-experienced patients who had at least one documented HbA<sub>1c</sub> value within the 12 weeks before switching to OW semaglutide. In addition, descriptive statistics were used for HbA<sub>1c</sub>, body weight target achievement, and safety data.</p><h3>Results</h3><p>Of the 3,505 patients included in the nine SURE studies, 651 switched to OW semaglutide from another GLP-1RA. GLP-1RA-experienced patients who switched to OW semaglutide demonstrated a 0.67%-point [95% confidence interval (CI) − 0.74; − 0.60, <i>p</i> < 0.0001] reduction in HbA<sub>1c</sub>, and a 3.69-kg [95% CI − 3.98; − 3.41, <i>p</i> < 0.0001] reduction in body weight over 30 weeks. A body weight reduction of ≥ 5% was achieved by 27.6% of patients, and 33.3% of patients with baseline HbA<sub>1c</sub> ≥ 7% achieved HbA<sub>1c</sub> < 7% at end of study. No new safety concerns were identified.</p><h3>Conclusions</h3><p>Data from this post hoc analysis suggest that, for those not adequately responding to treatment with other GLP-1RAs, switching to OW semaglutide could provide additional glycemic and weight benefits with the convenience of an OW dosing regimen.</p><h3>Graphical abstract</h3><p>A graphical abstract is available with this article.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>\",\"PeriodicalId\":7482,\"journal\":{\"name\":\"Advances in Therapy\",\"volume\":\"42 2\",\"pages\":\"788 - 800\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s12325-024-03000-x.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12325-024-03000-x\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-024-03000-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
在临床实践中，研究成人2型糖尿病患者从另一种胰高血糖素样肽-1受体激动剂（GLP-1RA）转为每周一次（OW）的semaglutide的结果。方法：这项事后分析使用了来自SemaglUtide真实世界证据（SURE）项目的数据，其中包括9项观察性研究，调查了2型糖尿病患者在常规临床实践中开始使用OW SemaglUtide的情况。使用随机系数调整的混合模型进行重复测量，分析glp - 1ra患者的糖化血红蛋白（HbA1c）、体重和体重指数的变化，这些患者在转换到OW semaglutide之前的12周内至少有一个记录的HbA1c值。此外，对HbA1c、体重达标和安全性数据进行描述性统计。结果：在9项SURE研究中纳入的3,505例患者中，651例从另一种GLP-1RA转为OW semaglutide。有glp - 1ra经历的患者改用OW西马鲁肽显示出0.67%点[95%可信区间(CI) - 0.74；- 0.60, p 1c, 3.69 kg [95% CI - 3.98；结论：这项事后分析的数据表明，对于那些对其他GLP-1RAs治疗没有充分反应的患者，改用OW semaglutide可以提供额外的血糖和体重益处，因为OW给药方案方便。
Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis
Introduction
To investigate outcomes in adults with type 2 diabetes who switched to once-weekly (OW) semaglutide from another glucagon-like peptide-1 receptor agonist (GLP-1RA) in clinical practice.
Methods
This post hoc analysis used data from the SemaglUtide Real-world Evidence (SURE) program, which included nine observational studies investigating the initiation of OW semaglutide in people with type 2 diabetes in routine clinical practice. Using a random coefficient-adjusted mixed model for repeated measurements, changes in glycosylated hemoglobin (HbA1c), body weight, and body mass index were analyzed for GLP-1RA-experienced patients who had at least one documented HbA1c value within the 12 weeks before switching to OW semaglutide. In addition, descriptive statistics were used for HbA1c, body weight target achievement, and safety data.
Results
Of the 3,505 patients included in the nine SURE studies, 651 switched to OW semaglutide from another GLP-1RA. GLP-1RA-experienced patients who switched to OW semaglutide demonstrated a 0.67%-point [95% confidence interval (CI) − 0.74; − 0.60, p < 0.0001] reduction in HbA1c, and a 3.69-kg [95% CI − 3.98; − 3.41, p < 0.0001] reduction in body weight over 30 weeks. A body weight reduction of ≥ 5% was achieved by 27.6% of patients, and 33.3% of patients with baseline HbA1c ≥ 7% achieved HbA1c < 7% at end of study. No new safety concerns were identified.
Conclusions
Data from this post hoc analysis suggest that, for those not adequately responding to treatment with other GLP-1RAs, switching to OW semaglutide could provide additional glycemic and weight benefits with the convenience of an OW dosing regimen.
Graphical abstract
A graphical abstract is available with this article.
期刊介绍：
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
